ImageneBio Stock: Why Analysts See 150% Upside Despite Competitor Setbacks
Leerink rates ImageneBio stock Outperform with $30 target, calling it "undervalued."
/ 921 items
#Healthcare↓
Lilly Acquires Adverum for One-Time Eye Disease Gene Therapy
Eli Lilly announces acquisition of Adverum Biotechnologies for up to $12.47 per share to advance Ixo-vec, a promising one-time gene therapy for age-related macular degeneration.
Kura Oncology Shares Jump 6% After $30M Milestone Payment for Cancer Drug Trial
Kura Oncology stock rises 6% in premarket trading after receiving $30 million milestone payment from Kyowa Kirin for Phase 3 cancer drug trial advancement.
HCA Healthcare Raises 2025 Profit Outlook on Strong Demand
HCA Healthcare (HCA) boosts 2025 earnings forecast as patients rush to use Obamacare benefits before subsidy changes take effect in 2026.
Berenberg Rates ATAI Life Sciences Buy with $12 Target on Strong Pipeline
Berenberg maintains Buy rating on ATAI Life Sciences (ATAI) with $12 price target, citing exceptional progress, strong pipeline momentum, and upcoming Phase 3 trials for psychedelic treatments.
JPMorgan Upgrades Kodiak Sciences on KSI-101 Potential
JPMorgan raises Kodiak Sciences rating to Overweight with $24 price target, citing reduced risk for KSI-101 drug treating eye inflammation and swelling.